Interpreting the Role of the Ramucirumab Plus Erlotinib Combination in EGFR+ NSCLC
Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS – Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab plus erlotinib was compared to erlotinib plus placebo in patients with EGFR-mutated non–small cell lung cancer. These data were presented at the 2019 ASCO Annual Meeting.
Marina C. Garassino, MD, medical consultant, Thoracic Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the results from the randomized phase III RELAY trial, in which the combination of ramucirumab (Cyramza) plus erlotinib (Tarceva) was compared to erlotinib plus placebo in patients with EGFR-mutated non–small cell lung cancer (NSCLC). These data were presented at the 2019 ASCO Annual Meeting.
Overall, the median progression-free survival (PFS) was 19.4 months by investigator assessment in the ramucirumab/erlotinib arm versus 12.4 months in the erlotinib-alone arm (HR, 0.591; 95% CI, 0.461-0.760; P <.0001). Garassino says it is still early for the overall survival data as they have not yet matured, but the results suggest that the PFS2 is longer in the combination arm as well. She also notes that the toxicity profile was manageable with the combination regimen.
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
